International trade is diverging. Washington is tightening access with aggressive tariffs, while China is lowering hurdles, especially in life sciences and advanced manufacturing. Nowhere is this clearer than in Hunan Province, where new regulations are designed to welcome international partners in biotechnology, pharmaceuticals, and medical technology.

The Global Sourcing & Investment Summit in Changsha (Nov 16–18, 2025) arrives at this pivotal moment, offering companies a unique platform to engage directly with Chinese regulators, industry leaders, and potential partners.

U.S. Tariffs: Rising Pressure

In the past months, the U.S. has imposed:

15% tariffs on most EU goods (Sept 1, 2025)

100% tariffs on branded pharmaceutical imports (Oct 1, 2025)

50% tariffs on steel and aluminum

These measures increase costs, restrict flexibility, and complicate global supply chains. For firms in biotech, medtech, pharma, and advanced manufacturing, they are forcing a strategic rethink.

China’s Alternative: Hunan’s New Regulation

On October 1, 2025, Hunan’s Cell and Gene Industry Promotion Regulations(See source in resource box) came into force.

Scope: The rules cover the full chain of activity—research, clinical trials, production, storage, logistics, adoption, and supervision—for cell and gene technologies and related medical products. They are embedded in China’s national development plan, aligning local initiatives with Beijing’s highest-level standards.

Key advantages for international firms:

Policy stability – Clear alignment with national standards and long-term planning.

Clinical access – Concentrated trials in leading tertiary hospitals accelerate collaboration and patient recruitment.

Expanded use – – Critically ill patients may access trial-stage therapies, generating real-world data and early adoption signals.

Global compliance – GMP/QMS standards with digital traceability simplify international integration.

Incentives – Funding, IP protection, insurance, customs facilitation, and preferential credit.

International cooperation – Free Trade Zone policies and Xiangjiang New District initiatives encourage joint ventures and multicenter clinical research.

Together, these measures make Hunan not only a regional hub but a national showcase and global gateway for life sciences and advanced manufacturing.

The Summit: Turning Policy into Opportunity

The Global Sourcing & Investment Summit, hosted at the Changsha International Convention Centre, will transform these policies into practical opportunities for international firms.

Highlights include:

Government engagement – Policy discussions with the Ministry of Commerce (MOFCOM), National Medical Products Administration (NMPA), Ministry of Science and Technology (MOST), provincial leaders, and Free Trade Zone authorities.

B2B matchmaking – Partnering with Chinese firms in regenerative medicine, diagnostics, medical devices, electronics, and more.

Site visits – Tours of industrial parks, tertiary hospitals, and research facilities.

Workshops – Practical sessions on resilient supply chains, localized R&D, IP protection, and risk management.

Why Now

With U.S. tariffs driving uncertainty and costs, global firms are seeking new corridors for growth. Hunan offers one of the most compelling alternatives: low tariffs, government-backed stability, a skilled workforce, advanced manufacturing, and world-class supply chains.

The Changsha Summit (Nov 16–18, 2025) is the entry point. It is where international businesses meet policymakers, build partnerships, and secure access to incentives—turning new regulation into real opportunity, exactly as China’s framework for cell and gene industries takes effect.

For inquiries or to reserve your space at the Global Sourcing and Investment Summit (November 16th, 2025 to November 18th, 2025) please contact either of the following:

Zatino Group

15 Harcourt Street, Dublin, D02 XY47

team@zatino.ie

+353 1 267 8018

Ireland Sino Institute

Cork, Ireland and Liaoning, China

team@irelandchinainstitute.eu

+86 13358993352